Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5292MR)

This product GTTS-WQ5292MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001243280.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5292MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6942MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ13609MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ15975MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ5470MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ10690MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ11871MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15006MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ6926MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW